<DOC>
	<DOCNO>NCT00758693</DOCNO>
	<brief_summary>Many chemotherapy combination may use treat patient chronic lymphocytic leukemia ( CLL ) . Although many option , single , best option agree upon cancer specialist . Bendamustine , medicine recently approve use United States , use combination rituximab previous study treat patient whose CLL return previous standard treatment . The purpose study determine whether bendamustine rituximab effective initial treatment CLL patient age 65 old .</brief_summary>
	<brief_title>Frontline Treatment With Bendamustine Combination With Rituximab Adults Age 65 Older With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients must histologically cytologically confirm chronic lymphocytic leukemia . A minimum one follow diseaserelated symptom must present : Weight loss ≥10 % within previous 6 month . Extreme fatigue ( ie , ECOG PS 2 ; work unable perform usual activity ) . Fevers great 100.5 '' F ≥ 2 week without evidence infection . Night sweat without evidence infection . Evidence progressive marrow failure manifest development , worsen , anemia and/or thrombocytopenia Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid therapy Massive ( ie , &gt; 6 cm leave costal margin ) progressive splenomegaly Massive nod cluster ( ie , &gt; 10 cm long diameter ) progressive lymphadenopathy Progressive lymphocytosis increase &gt; 50 % 2month period , anticipate double time le 6 month Marked hypogammaglobulinemia development monoclonal protein absence criterion active disease sufficient protocol therapy No prior therapy CLL allow . Participants may take corticosteroid previously must ≥ 28 day last dose prior enrolment . Age &gt; 65 year . Life expectancy great 1 year . ECOG performance status well equal 2 . Patients must normal organ marrow function define : total bilirubin within normal institutional limit unless result documented hemolysis AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal creatinine within normal institutional limit OR creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal Ability understand willingness sign write informed consent document . Patients previous chemotherapy radiotherapy treatment CLL . Patients may receive investigational agent . Patients know brain involvement exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . History allergic reaction attribute compound similar chemical biologic composition bendamustine rituximab . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . HIVpositive patient ineligible patient increase risk lethal infection treat marrowsuppressive therapy . Patients known history viral hepatitis , exception Hepatitis A recover . Patients require concomitant treatment CYP1A2 inhibitor include : Cimetidine , Ciprofloxacin , Fluvoxamine , Ticlopidine .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Treanda</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
</DOC>